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Adjuvant chemotherapy in upper tract urothelial carcinoma 
(the POUT trial): a phase 3, open-label, randomised 
controlled trial
Alison Birtle, Mark Johnson, John Chester, Robert Jones, David Dolling, Richard T Bryan, Christopher Harris*, Andrew Winterbottom*, 
Anthony Blacker, James W F Catto, Prabir Chakraborti, Jenny L Donovan, Paul Anthony Elliott, Ann French, Satinder Jagdev, Benjamin Jenkins, 
Francis Xavier Keeley Jr, Roger Kockelbergh, Thomas Powles, John Wagstaff, Caroline Wilson, Rachel Todd, Rebecca Lewis, Emma Hall
Summary
Background Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis 
than urothelial carcinomas of the urinary bladder. No international consensus exists on the benefit of adjuvant 
chemotherapy for patients with UTUCs after nephroureterectomy with curative intent. The POUT (Peri-Operative 
chemotherapy versus sUrveillance in upper Tract urothelial cancer) trial aimed to assess the efficacy of systemic 
platinum-based chemotherapy in patients with UTUCs.
Methods We did a phase 3, open-label, randomised controlled trial at 71 hospitals in the UK. We recruited patients 
with UTUC after nephroureterectomy staged as either pT2–T4 pN0–N3 M0 or pTany N1–3 M0. We randomly allocated 
participants centrally (1:1) to either surveillance or four 21-day cycles of chemotherapy, using a minimisation algorithm 
with a random element. Chemotherapy was either cisplatin (70 mg/m²) or carboplatin (area under the curve 
[AUC]4·5/AUC5, for glomerular filtration rate <50 mL/min only) administered intravenously on day 1 and 
gemcitabine (1000 mg/m²) administered intravenously on days 1 and 8; chemotherapy was initiated within 90 days of 
surgery. Follow-up included standard cystoscopic, radiological, and clinical assessments. The primary endpoint was 
disease-free survival analysed by intention to treat with a Peto-Haybittle stopping rule for (in)efficacy. The trial is 
registered with ClinicalTrials.gov, NCT01993979. A preplanned interim analysis met the efficacy criterion for early 
closure after recruitment of 261 participants.
Findings Between June 19, 2012, and Nov 8, 2017, we enrolled 261 participants from 57 of 71 open study sites. 
132 patients were assigned chemotherapy and 129 surveillance. One participant allocated chemotherapy withdrew 
consent for data use after randomisation and was excluded from analyses. Adjuvant chemotherapy significantly 
improved disease-free survival (hazard ratio 0·45, 95% CI 0·30–0·68; p=0·0001) at a median follow-up of 
30·3 months (IQR 18·0–47·5). 3-year event-free estimates were 71% (95% CI 61–78) and 46% (36–56) for 
chemotherapy and surveillance, respectively. 55 (44%) of 126 participants who started chemotherapy had acute 
grade 3 or worse treatment-emergent adverse events, which accorded with frequently reported events for the 
chemotherapy regimen. Five (4%) of 129 patients managed by surveillance had acute grade 3 or worse emergent 
adverse events. No treatment-related deaths were reported.
Interpretation Gemcitabine–platinum combination chemotherapy initiated within 90 days after nephroureterectomy 
significantly improved disease-free survival in patients with locally advanced UTUC. Adjuvant platinum-based 
chemotherapy should be considered a new standard of care after nephroureterectomy for this patient population.
Funding Cancer Research UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Upper tract urothelial carcinoma (UTUC; transitional 
cell carcinoma of the ureter or renal pelvis) is rare, 
occurring in around two people per 100 000 population 
in high-income countries. Scant symptoms and delayed 
diagnosis mean that tumours are often muscle-invasive 
or locally advanced at presentation (56%), resulting in 
poorer survival figures than for urothelial carcinoma of 
the urinary bladder. More than 50% of patients diag-
nosed with UTUC die as a result of their disease, despite 
systemic platinum-based chemotherapy after local or 
metastatic recurrence.1 Improved management of early-
stage disease, therefore, has the potential to save lives. 
At the inception of this study, systemic treatment had 
no proven role for locally advanced UTUC.2 Nephro-
ureterectomy followed by surveillance has re mained the 
routine treatment for localised UTUC.1
UTUC shares several clinicopathological features with 
muscle-invasive urothelial (transitional cell) carcinoma 
of the bladder. Robust survival improvements are seen 
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with platinum-based chemotherapy in patients with 
urothelial bladder cancer, in both the neoadjuvant and 
metastatic settings.3–5 Similar benefits of platinum-based 
palliative chemotherapy have been seen for UTUC and 
urothelial bladder cancer at advanced stages.6 Thus, 
a clear rationale exists for investigating perioperative, 
platinum-based chemotherapy in patients with UTUC.
Because of the strength of evidence showing survival 
gain, neoadjuvant chemotherapy is the accepted standard 
of care for muscle-invasive bladder cancer. Although a 
neoadjuvant approach is attractive for patients with UTUC, 
particularly when the loss of renal function asso ciated with 
nephrectomy is considered, the unreliability of preoperative 
UTUC staging and histopathology would probably result 
in overtreatment for some patients and undertreatment 
for others.7 Previous studies of adjuvant chemotherapy in 
UTUC are largely retrospective, with low statistical power 
and conflicting conclusions,8–10 pro viding insufficient 
evidence to recommend perioperative chemotherapy. Thus, 
for many patients with muscle-invasive UTUC, surgery 
alone is considered the standard approach.
Patient-reported outcome data for this rare population 
are also absent, with most available published work at 
the outset of this trial focusing on short-term outcomes 
after nephroureterectomy and no data obtained within 
the context of randomised controlled trials. We aimed 
to prospectively assess in a randomised controlled trial 
(the POUT trial) the effect of adjuvant platinum-based 
chemotherapy on disease-free survival, overall survival, 
safety, and quality of life after radical nephroureterectomy 
in patients with locally advanced UTUC.
Methods
Study design
POUT is a phase 3, parallel group, open-label, randomised 
controlled trial done at 71 National Health Service (NHS) 
hospitals in the UK. An intervention was included to 
understand and then support recruitment to the trial.11 
Eligible patients were aged at least 16 years, had received 
en-bloc radical nephroureterectomy for UTUC (including 
resection of all radiologically or macroscopically abnormal 
nodes), were postoperatively staged with either muscle-
invasive (pT2–pT4, Nany) or lymph node-positive (pTany, 
N1–3) metastasis-free (M0) disease with predominantly 
transitional cell carcinoma histology, and were fit to receive 
adjuvant chemotherapy within 90 days after surgery.
Formal extended lymph-node dissection was not 
mandated. Participants with lymph-node involvement 
identified on preoperative imaging or during surgery 
had all grossly abnormal nodes resected. Postoperative 
imaging was mandated for these patients before 
randomisation; those with residual lymphadenopathy 
as ascertained by the local investigator were excluded. 
Participants had satisfactory haematological and bio-
chemical blood profiles and a glomerular filtration rate 
(GFR) of 30 mL/min or higher.
Participants were recruited by their clinical care teams 
and provided written informed consent before enrolment. 
Regulatory approvals were obtained before trial activation 
from the Medicines and Healthcare products Regulatory 
Agency (MHRA) and the North West–Greater Manchester 
South research ethics committee (11/NW/0782). The 
POUT trial was undertaken according to the principles of 
Research in context
Evidence before this study
Before this study, findings of a literature review available online 
in 2010 (Audenet et al, 2013) showed that no level 1 
randomised trial evidence was available assessing the efficacy of 
systemic chemotherapy for locally advanced upper tract 
urothelial carcinoma (UTUC). The paucity of research is partly 
because of the rarity of the disease. Undersized or retrospective 
studies had not shown a convincing survival benefit for 
chemotherapy. Guidelines from the European Association of 
Urology, therefore, recommended nephroureterectomy 
followed by surveillance as the standard of care. Most urothelial 
carcinomas (in both UTUC and bladder cancer) originate in the 
transitional epithelium (transitional cell carcinoma). It is logical, 
therefore, to consider data from trials of systemic bladder cancer 
treatment for signals to indicate whether chemotherapy could 
be efficacious in UTUC. Studies of perioperative chemotherapy 
for primary urothelial carcinoma of the bladder suggested 
localised urothelial carcinoma was chemosensitive, with 
(on meta-analysis) cisplatin-based neoadjuvant chemotherapy 
showing an absolute improvement of 5% in overall survival at 
5 years (hazard ratio 0·86, 95% CI 0·77–0·95; p=0·003). 
Therefore, a comparable trial in UTUC was justified, particularly 
in view of the inferior stage-for-stage outcomes in UTUC when 
compared with bladder urothelial carcinoma. Challenges of 
obtaining definitive histology and accurate staging for UTUC 
before nephroureterectomy risk either undertreatment or 
overtreatment with neoadjuvant therapy. The POUT trial was, 
therefore, designed as a phase 3 randomised trial of adjuvant 
platinum-based chemotherapy, intended to provide, for the first 
time, robust evidence regarding its efficacy in UTUC.
Added value of this study
To the best of our knowledge, our study is the largest 
randomised controlled clinical trial done exclusively in patients 
with UTUC worldwide.
Implications of all the available evidence
We have shown that giving adjuvant platinum-based 
chemotherapy within 90 days after nephroureterectomy 
reduces subsequent rates of disease recurrence. Our data, 
therefore, suggest that adjuvant platinum-based chemotherapy 
should be recommended as a new standard of care after 
nephroureterectomy for all patients with locally advanced UTUC 
in whom there are no definitive contraindications to 
chemotherapy.
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Good Clinical Practice, and sponsored by The Institute of 
Cancer Research (ICR). The Clinical Trials and Statistics 
Unit at ICR (ICR-CTSU) coordinated the trial, did central 
statistical data moni toring, and undertook all analyses. 
The trial management group was overseen by indepen-
dent data monitoring and trial steering committees 
(appendix p 12). The full study protocol is available in the 
appendix (pp 13–66).
Randomisation and masking
Treatment allocation was done centrally by ICR-CTSU 
using a minimisation algorithm incorporating a random 
element. Balancing factors were planned platinum agent 
(cisplatin vs carboplatin), preoperative radiologically or 
pathologically assessed nodal involvement (N0 vs N1 
vs N2 vs N3), status of microscopic surgical margins 
(positive vs negative), and treating centre. Participants 
were randomly allocated (1:1) either surveillance or 
chemotherapy. Treatment allocation was not masked.
Procedures
Participants allocated chemotherapy received four 21-day 
cycles of platinum-based combination chemotherapy, to 
begin within 14 days after randomisation. Gemcitabine 
(1000 mg/m²) was given on days 1 and 8 of each cycle. 
Either cisplatin (70 mg/m²) or carboplatin (area under the 
curve [AUC]4·5 or AUC5, according to local practice, 
prespecified for each treatment centre) was given on 
day 1. Impaired renal function (GFR ≥30 mL/min and 
<50 mL/min) was the only permitted reason to give carbo-
platin rather than cisplatin. Protocol-specified recommend-
ations were for chemotherapy to begin within 90 days of 
nephro ureterectomy, for gemcitabine to be given as a 
30-min intravenous infusion in 500 mL normal saline, 
cisplatin as a 4-h intravenous infusion in 1 L saline, and 
carboplatin as a 1-h intravenous infusion. Use of generic 
agents was allowed; no recommended manufacturer was 
specified. Hydration and infusion rates were in accordance 
with local practice. The protocol-recommended calculation 
of GFR was by the Cockcroft and Gault method; however, 
use of the Wright formula or estimation by radioiso-
tope clearance were also permitted. Participating sites 
prespecified their intended assessment method before 
activation and were requested to use the same GFR 
assessment method for a participant throughout the study. 
Patients otherwise unsuitable to receive cisplatin were not 
permitted to join the trial to minimise the potential 
confounding effects of frailty and comorbidity. All parti-
cipants receiving chemotherapy had haema tology and 
serum biochemistry assessments and their GFR was 
estimated and body surface area calculated before every 
cycle of chemotherapy.
Adverse events during every chemotherapy cycle were 
assessed by the local investigator using National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0. Protocol-specified dose 
modifications were permitted for toxic effects of CTCAE 
grade 3 or worse. Patients intended to receive cisplatin 
were to switch to carboplatin if the estimated GFR fell to 
30–49 mL/min. If the GFR fell from 70 mL/min or higher 
to 50–69 mL/min then the cisplatin dose was allowed to 
be split across 2 consecutive days. Participants allocated 
surveil lance underwent adverse event assessment every 
3 weeks after randomisation to mirror the assessment 
schedule of participants allocated chemotherapy.
Participants in both study groups were followed up at 
3, 6, 9, and 12 months, then every 6 months to 36 months 
from randomisation, regardless of whether chemotherapy 
was complete, and annually thereafter. Assessment of 
disease recurrence included either plain film radiography 
or cross-sectional imaging (CT) of the thorax plus CT of 
the abdomen and pelvis at 3, 6, 9 (thorax only), 12, 18, 24, 30 
(thorax only), and 36 months, then annually to 60 months. 
Cystoscopy was done every 6 months to 24 months, 
then annually to 60 months to detect recurrence in the 
lower urinary tract. Follow-up assessments were done in 
accordance with standard practice in the UK at the time. 
Assessment of adverse events was done at every follow-
up visit to 24 months. Participants in both study groups 
who had disease recurrence were permitted to receive 
any appropriate further treatment as clinically indicated, 
including platinum–gemcitabine chemotherapy.
Participants in an optional patient-reported quality-of-life 
substudy were asked to complete on paper the European 
Organisation for Research and Treatment of Cancer 
(EORTC) quality-of-life of cancer patients questionnaire 
(QLQ-C30) and the EuroQol five dimensions five levels 
questionnaire (EQ-5D-5L) at baseline and before cycle 
three (week 7) and at 3 months, then at 6, 12, and 24 months 
post randomisation.
Outcomes
The primary endpoint was disease-free survival according 
to local assessment and was defined as time from 
randomisation to either first recurrence in the tumour 
bed, first metastasis, or death from any cause. Recurrence 
and metastasis could be established either radiologically 
or pathologically. Patients were censored at the date of 
diagnosis of a second primary cancer (including muscle-
invasive bladder cancer and contralateral UTUC). New 
non-muscle-invasive bladder cancer was not regarded 
as an event or a reason to censor, although such events 
were recorded for future analysis. Secondary end-
points included metastasis-free survival, overall survival, 
treatment compliance, acute toxicity, late toxicity, and 
patient-reported quality of life.
Statistical analysis
The trial was designed to detect a hazard ratio (HR) 
of 0·65 in favour of chemotherapy, equivalent to a 
15% absolute improvement in 3-year disease-free sur-
vival (from 40% to 55%, which was chosen to correspond 
with the magnitude of benefit noted for chemotherapy 
in muscle-invasive bladder cancer), with a two-sided 
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signifi cance of 5% and 80% power. On this basis, target 
recruitment was 345 participants (172 events), including 
a 2% inflation for loss to follow-up.
Time-to-event endpoints were analysed according to 
the intention-to-treat principle using the log-rank test 
and are presented using Kaplan-Meier plots. Estimates 
of treatment effect (with 95% CIs) were made using 
unadjusted and adjusted Cox regression models, with 
an HR less than 1 favouring chemotherapy. Adjusted 
models included planned chemotherapy type, nodal 
status and microscopic margin status (balancing factors) 
and pathological stage. A prespecified subgroup ana-
lysis was done of adjustment factors. The proportional 
hazards assumption of the Cox model held when tested 
with Schoenfeld residuals. Two-sided p values less than 
0·05 were judged significant.
The incidence of acute treatment-emergent adverse 
events, defined for both study groups as an increase 
in grade of any adverse event from baseline up to 
the 3-month timepoint, was compared by treatment 
received using the Wilcoxon rank-sum test (worst grade) 
and the χ² test (proportion grade 3 or worse). Adverse 
events reported by more than 10% of participants in 
either group, or with significant differences between 
study groups using the Wilcoxon rank-sum test with a 
1% significance level (to make some adjustment for 
multiple testing), were judged meaningful. Toxicity and 
treatment compliance data are reported in the safety 
population by treatment received at cycle one. Treatment 
compliance was assessed in all patients who received at 
least one dose of gemcitabine, cisplatin or carboplatin. 
When comparing the frequency of each adverse event 
type, we excluded participants who were not assessed 
for that adverse event type in the first 3 months of 
treatment (or equivalent timepoints for those allocated 
surveillance).
The global health score of the EORTC QLQ-C30 
reported up to 12 months was summarised according to 
randomised allocation on an intention-to-treat basis. 
Data were analysed in accordance with the QLQ-C30 
scoring manual. Change from baseline was compared 
between randomised groups using the ANCOVA model, 
adjusting for baseline score. Allowance for multiple 
testing was made by assessing scores at 3 months and 
12 months only, with p values less than 0·01 judged 
significant; as a result, 99% CIs were used.
Accumulating safety and efficacy data were reviewed in 
confidence annually throughout the trial by an inde-
pendent data monitoring committee. A Peto-Haybittle 
stopping rule (p<0·001) addressed both efficacy and 
inefficacy in disease-free survival.
Analyses are based on a snapshot of data taken on 
Nov 7, 2018, and include data from all follow-up visits up 
Figure 1: Trial profile
Dotted lines indicate crossovers. ITT=intention to treat. 
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to and including May 31, 2018. This snapshot supersedes 
that used for the interim analysis, which led to the 
decision to close the trial early so that complete treatment 
and 3-month toxicity data could be reported. Analyses 
were done using Stata version 15.1.
This study is registered with the ISRCTN registry 
(ISRCTN98387754), ClinicalTrials.gov (NCT01993979), 
and Cancer Research UK (CRUK/11/027).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
Between June 19, 2012, and Nov 8, 2017, 261 participants 
were recruited from 57 of 71 open sites (appendix pp 2–4), 
of whom 132 patients were allocated chemotherapy and 
129 were allocated surveillance. 260 participants were 
included in the intention-to-treat population; one partici-
pant with drew consent for data use after randomisation 
and is not included in any analyses (figure 1). Recruitment 
closed early on the recommendation of the independent 
data monitoring committee, having met the early stopping 
criterion for efficacy. At the point of trial closure, the 
independent data monitoring committee recommended 
that all participants who were still within the 90-day 
window from nephroureterectomy should be offered 
chemotherapy. Two participants allocated surveillance 
and still within this timeframe crossed over to receive 
chemotherapy but were included in the surveillance group 
for the intention-to-treat analysis (figure 1).
The median age of participants was 68·5 years 
(IQR 62·0–74·1; table). 245 (94%) of 260 participants 
were staged pT2–T3; of these, 223 (91%) were also 
staged N0 (appendix p 5). 166 (64%) participants had 
GFR of 50 mL/min or higher. Median follow-up was 
30·3 months (IQR 18·0–47·5).
Seven of 131 participants allocated chemotherapy did 
not start treatment. 95 (75%) of 126 participants who 
started chemo therapy (including two patients who 
switched from surveillance after closure to recruitment) 
received four cycles of treatment. The proportion of 
participants starting chemotherapy who received four 
cycles of treatment did not differ by planned platinum 
agent (57 [75%] of 76 were planned to receive 
gemcitabine–cisplatin and 38 [76%] of 50 were planned 
to received gemcitabine–carboplatin; p=0·90).
31 participants discontinued chemotherapy early 
(clinician’s decision [n=11], toxicity [n=10], patient’s 
choice [n=8], or another unspecified reason [n=2]). Of the 
95 participants receiving four cycles of chemotherapy, 
52 started with gemcitabine–cisplatin and 43 started 
with gemcitabine–carboplatin. 41 (58%) of 71 participants 
who started cisplatin completed four cycles of cisplatin 
Surveillance (n=129) Chemotherapy (n=131) Total (n=260)
Sex
Male 83 (64%) 93 (71%) 176 (68%)
Female 46 (36%) 38 (29%) 84 (32%)
Age group (years)
<50 5 (4%) 5 (4%) 10 (4%)
50–59 24 (19%) 19 (15%) 43 (17%)
60–69 52 (40%) 50 (38%) 102 (39%)
70–79 40 (31%) 51 (39%) 91 (35%)
≥80 8 (6%) 6 (5%) 14 (5%)
Median (IQR) 66·5 (61·5–73·3) 69·2 (57·8–75·0) 68·5 (62·0–74·1)
WHO performance status
0 85 (66%) 90 (69%) 175 (67%)
1 43 (33%) 40 (31%) 83 (32%)
Missing data 1 (1%) 1 (1%) 2 (1%)
Smoking status
Current 14 (11%) 13 (10%) 27 (10%)
Previous 67 (52%) 70 (53%) 137 (53%)
Never 47 (36%) 48 (37%) 95 (37%)
Missing data 1 (1%) 0 (0%) 1 (<1%)
Concomitant drugs
No 27 (21%) 25 (19%) 52 (20%)
Yes 102 (79%) 105 (80%) 207 (80%)
Antihypertensive 51 (40%) 60 (46%) 111 (43%)
Analgesic 30 (23%) 21 (16%) 51 (20%)
Antidiabetes 11 (9%) 15 (11%) 26 (10%)
Anticoagulant 19 (15%) 9 (7%) 28 (11%)
Antiangina 7 (5%) 7 (5%) 14 (5%)
Other 80 (62%) 77 (59%) 157 (60%)
Missing data 0 (0%) 1 (1%) 1 (<1%)
Pathological T stage
pT2 30 (23%) 44 (34%) 74 (28%)
pT3 88 (68%) 83 (63%) 171 (66%)
pT4 11 (9%) 4 (3%) 15 (6%)
Nodal stage*
N0 118 (91%) 118 (90%) 236 (91%)
N1 7 (5%) 8 (6%) 15 (6%)
N2 4 (3%) 4 (3%) 8 (3%)
N3 0 (0%) 1 (1%) 1 (<1%)
GFR (mL/min)
30–49 45 (35%) 49 (37%) 94 (36%) 
≥50 84 (65%) 82 (63%) 166 (64%) 
Site of tumour
Renal pelvis 44 (34%) 47 (36%) 91 (35%)
Ureter 42 (33%) 47 (36%) 89 (34%)
Both 40 (31%) 37 (28%) 77 (30%)
Missing data 3 (2%) 0 (0%) 3 (1%)
Type of surgery
Open 17 (13%) 21 (16%) 38 (15%)
Laparoscopic 104 (81%) 109 (83%) 213 (82%)
Robotic 4 (3%) 1 (1%) 5 (2%)
Other† 1 (1%) 0 (0%) 1 (<1%)
Missing data 3 (2%) 0 (0%) 3 (1%)
(Table continues on next page)
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(a further patient received only gemcitabine on cycle 
four). 198 (91%) of 218 cycles of gemcitabine–cisplatin 
and 186 (83%) of 223 cycles of gemcitabine–carboplatin 
were delivered without a dose reduction. 16 (21%) of 
76 participants intended for cisplatin switched to 
carbo platin because of a post-randomisation drop in 
GFR (figure 1). Six participants switched before the start 
of treatment and a further ten changed chemo therapy 
regimen from gemcitabine–cisplatin to gemcitabine–
carboplatin at cycle two or later; of these, six switches 
were because of a reduction in GFR, as per protocol, 
two were attributable to suspected renal impairment, and 
two were because of grade 3 toxicity (joint pain or 
tinnitus). One (2%) of 50 participants planned to receive 
carboplatin switched to cisplatin because of a post-
randomisation increase in GFR before treatment began.
Fewer disease-related events contributing to the 
primary endpoint were reported in participants allocated 
chemotherapy (35 [27%] of 131) than in participants 
allocated surveillance (60 [47%] of 129). Chemotherapy 
conferred a 55% reduction in relative risk of disease 
recurrence or death (HR 0·45, 95% CI 0·30–0·68; log-
rank p=0·0001; figure 2A). 3-year disease-free survival 
estimates were 71% (95% CI 61–78) in patients allo cated 
chemotherapy and 46% (36–56) in those allocated 
surveillance, with an estimated absolute difference of 
25% (95% CI 11–38). Median disease-free survival 
among patients allocated surveillance was 29·8 months 
(IQR 6·3–not reached; 95% CI 13·6–incalculable), and 
was not reached among those allocated chemotherapy. 
The benefit of chemotherapy was largely unchanged after 
adjustment for known prognostic factors (HR 0·46, 
95% CI 0·30–0·71; p=0·0004; appendix p 6). Sensitivity 
analyses, including second primary muscle-invasive 
bladder cancers as recurrence events, gave similar results 
(appendix p 7). No heterogeneity of disease-free survival 
treatment effect was seen by prespecified balancing 
factors or tumour stage (figure 3).
Participants allocated chemotherapy also had a lower 
risk of metastasis or death (HR 0·48, 95% CI 0·31–0·74; 
log-rank p=0·0007; figure 2B). 3-year event-free rates 
were 71% (95% CI 60–79) among patients allocated 
chemotherapy and 53% (42–63) among those allocated 
surveillance, with an estimated absolute difference of 
17% (95% CI 4–31). Results were similar in multivariable 
analyses (appendix p 6).
Analysis of overall survival is planned once 88 deaths 
have occurred or all participants have at least 2 years of 
follow-up (whichever occurs first). 62 deaths have been 
recorded to date (24 assigned chemotherapy and 
38 assigned surveillance). 49 deaths were attributed to 
UTUC, four to bladder cancer, one to other malignant 
disease, and eight to other causes. No treatment-related 
deaths were reported.
Grade 3 or worse acute treatment-emergent adverse 
events were reported for 55 (44%) of 126 participants 
who started chemotherapy (31 [44%] of 71 who started 
gemcitabine–cisplatin and 24 of 55 [44%] who started 
gemcitabine–carboplatin) compared with five (4%) of 
129 managed by surveillance (p<0·0001). For each 
chemo therapy regimen, adverse events accorded with 
those frequently reported in routine clinical practice 
Figure 2: Disease-free survival and metastasis-free survival
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Microscopic margin status
Positive 14 (11%) 17 (13%) 31 (12%)
Negative 115 (89%) 114 (87%) 229 (88%)
Number of lymph nodes dissected
0 92 (71%) 86 (66%) 178 (68%)
1–3 21 (16%) 25 (19%) 46 (18%)
4–9 6 (5%) 6 (5%) 12 (5%)
≥10 6 (5%) 3 (2%) 9 (3%)
Missing data 4 (3%) 11 (8%) 15 (6%)
Data are n (%), unless otherwise stated. GFR=glomerular filtration rate. *Ascertained radiologically when pathological 
staging was not available. †Kidney and ureter freed laparoscopically and removed through an open incision at the iliac 
fossa.
Table: Participants’ and tumour characteristics at trial entry
See Online for appendix
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(appendix pp 8–11). Participants who received chemo-
therapy were more likely than those managed by surveil-
lance to have grade 3 or worse decreases in neutrophils 
(45 [36%] of 126) and platelet count (13 [10%]), nausea 
(eight [6%]), febrile neutropenia (eight [6%]), and 
vomiting (seven [6%]). 54 serious adverse events were 
reported for 42 (32%) of 126 par ticipants who received 
che motherapy; 39 events were related to treatment. 
Analysis of late toxicity is planned once 2-year data are 
available for all participants.
256 (98%) of 261 study participants consented to take 
part in the optional patient-reported quality-of-life study, 
including one participant who withdrew consent to use 
data after randomisation. Questionnaire return rates 
did not differ by allocated study group at any timepoint. 
Questionnaires were returned by 243 (95%) of 255 par ti-
cipants at baseline (119 [95%] of 125 allocated surveil-
lance and 124 [95%] of 130 allocated chemotherapy), 
208 (82%) of 255 at 3 months (101 [81%] of 125 
and 107 [82%] of 130, respec tively), and 166 (70%) of 
237 at 12 months (78 [70%] of 112 and 88 [70%] of 125, 
respectively). Mean overall global health status score at 
baseline was 77% (SD 19) for the chemotherapy group 
and 76% (19) for the surveillance group. Overall global 
health status was lower during chemotherapy (before 
cycle 3) and immediately afterwards (at 3 months) in 
participants allocated chemotherapy versus surveil lance. 
This difference had resolved by 6 months (figure 4). 
A full quality-of-life data analysis is planned once 2-year 
data are available for all participants.
Discussion
To our knowledge, the POUT trial is the largest reported 
in this patient population. Our findings show that 
gemcitabine–platinum combination chemotherapy initi-
ated within 90 days after nephroureterectomy signifi cantly 
improves disease-free survival in patients with locally 
advanced UTUC. Chemotherapy was also associated with 
improved metastasis-free survival, with acceptable acute 
toxic effects consistent with existing data,12 and with no 
more than a transient effect on patient-reported quality of 
life.
The relative effect on survival of carboplatin and 
cisplatin remains unclear in urothelial carcinoma with-
out sufficient data from clinical trials incorporating a 
direct randomised comparison between the two agents. 
Findings of a meta-analysis of outcomes of patients with 
advanced urothelial carcinoma treated with platinum-
based chemotherapy showed superior tumour response 
rates in trials of cisplatin compared with those of 
carboplatin.13 In the POUT trial, a GFR greater than 
50 mL/min was deliberately selected as the criterion 
for cisplatin delivery. Appropriate selection of the 
cisplatin-eligible population was an important consid-
eration during development of the POUT trial, with 
input sought from potential investigators. Although we 
acknowledge that a GFR lower than 60 mL/min forms 
part of the Galsky definition of being cisplatin unfit, 
routine practice in the UK for treatment of patients with 
non-UTUC tumours is to use a cutoff point for GFR of 
greater than 50 mL/min. In view of UK oncologists’ 
experience and familiarity with use of cisplatin in 
patients without UTUC, and our wish not to exclude 
patients in the rare UTUC setting for whom cisplatin 
could be a feasible treatment, we judged that the 
criterion for switching to carboplatin at a GFR less than 
50 mL/min was appropriate.
Acknowledging low power for formal statistical testing, 
our analysis showed no apparent heterogeneity of 
treatment effect and results were consistent across 
prespecified subgroups, including planned platinum 
agent. POUT trial data, therefore, support the use of 
adjuvant platinum-based chemotherapy in all patients 
who have undergone nephroureterectomy with curative 
intent. Although cisplatin should be the preferred 
agent when possible, our results suggest that patients 
for whom cisplatin is contraindicated because of poor 
renal function could still derive benefit from the 
Figure 3: Subgroup analysis of disease-free survival
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alternative gemcitabine–carboplatin regimen. Indivi-
duals with resected nodal disease and those with micro-
scopically positive margins at surgery should also be 
offered adjuvant platinum-based chemotherapy, subject 
to their fitness for systemic treatment.
The limitations of our study largely relate to pragmatic 
decisions taken during study development to enable 
successful recruitment to this trial in a rare patient 
population while preserving our ability to address the 
primary endpoint.
At the time of study development, a feasibility survey 
across all UK sites confirmed that formal nodal dissection 
was not part of standard care, nor were data to support 
this procedure strong. Therefore, nodal dissection was 
not mandated in the protocol because it was deemed 
inappropriate to do so. Ongoing debate around the 
survival benefits of extended abdominal lymph node 
dissection (ELND) in UTUC14 meant that this procedure 
was only needed for patients with observable lymph-
adenopathy on baseline imaging. Since most participants 
had limited lymph node dissection (ie, removal of all 
macroscopic visible nodes), occult metastases might 
have been overlooked in some patients categorised as 
N0, because a proportion were likely to have been 
microscopically node-positive. A clear benefit from 
adjuvant chemotherapy was seen in the N0 group of 
patients; therefore, whether standard use of nodal 
dissection would offer additional benefit is uncertain. 
The role of ELND in N0 disease remains a subject for 
future studies.
We acknowledge that disease-free survival is not 
regarded as a fully validated surrogate of overall survival 
after nephroureterectomy for UTUC.14 However, in a rare 
disease such as UTUC, a suitably powered trial with 
overall survival as the primary endpoint was not judged 
feasible. A placebo control group was judged inappro-
priate; use of identical follow-up procedures in both 
study groups aimed to minimise the risk of assessment 
bias. Although mature survival data (as a secondary 
endpoint) are not yet available, the large improvement in 
disease-free survival we noted for the primary endpoint, 
together with improved metastasis-free survival recorded 
as a secondary endpoint, strongly suggest that patients 
have better outcomes with chemotherapy than without. 
In view of the rarity of UTUC and the urgent need 
to improve outcomes, we believe that evidence is now 
sufficient to advocate use of gemcitabine–platinum com-
bination chemotherapy as a standard of care.
Whether perioperative systemic therapy would be most 
effective for UTUC in the neoadjuvant or adjuvant setting 
remains contentious. Meaningful pathological complete 
response rates15 and, in retrospective case series, sur-
vival benefits16 suggest similar potential advantages with 
neoadjuvant therapy in UTUC to those seen in bladder 
cancer. Furthermore, potentially nephro toxic cisplatin-
based chemotherapy might be safer and more feasible for 
UTUC if given before nephro ureter ectomy, when patients 
retain maximum renal function. Some patients were 
probably excluded from the POUT trial (and might be 
similarly excluded from adjuvant chemotherapy in real-
life practice) because of insufficient recovery after surgery. 
These patients might be better served with neoadjuvant 
chemotherapy, albeit with the risk that the toxic effects 
of chemotherapy could prevent some individuals from 
proceeding with curative surgery. We had considered a 
trial of neoadjuvant chemotherapy when developing the 
POUT trial concept; however, we had concerns about the 
reliability of preoperative staging and histology in muscle-
invasive UTUC.7 Before starting the POUT trial, we did 
a feasibility survey across all potential UK investigators, 
which strongly supported an adjuvant rather than a 
neoadjuvant study for the reasons we have outlined. 
Two patient focus groups undertaken during study 
development explored the different approaches, and their 
feedback favoured an adjuvant trial. Investigation of the 
relative feasibility of adjuvant and neoadjuvant cytotoxic 
chemotherapy in UTUC is underway (NCT02969083). 
Although the POUT trial has shown superiority of adju-
vant chemotherapy over surgery alone, it is not clear that 
patients previously planned for neoadjuvant chemo-
therapy should now defer treatment until surgery is 
complete. However, until further robust evidence 
becomes available, we propose that adjuvant treatment 
should be considered the preferred setting for future 
trials of perioperative chemotherapy in UTUC.
Previous studies adding a third agent to gemcitabine–
platinum combinations have met with little success in 
advanced disease,17–19 partly because of the high burden 
of toxicity. However, data suggest potential benefits 
from two new classes of agents, fibroblast growth factor 
receptor (FGFR) inhibitors and immune checkpoint 
therapeutics. Increased understanding of the biology of 
UTUC suggests that distinct molecular differences exist 
between UTUC and bladder urothelial carcinomas.20 
Higher proportions of FGFR alterations and luminal-like 
urothelial cancer signatures have been noted in UTUC21 
than in bladder cancer.22 Because FGFR alterations are 
associated with high response rates to FGFR inhibitors 
and luminal-like urothelial cancer signatures with 
low response rates to chemotherapy in advanced uro-
thelial cancers, investigation of orally bioavailable FGFR 
inhibitors (eg, erdafitinib alone or in combination with 
gemcitabine–platinum regimens) in molecularly selected 
patient cohorts might have particular value.23–26 Efficacy 
of check point inhibitors (eg, pembrolizumab and 
atezolizumab) in advanced urothelial carcinoma27–29 has 
prompted trials of immunotherapy in the perioperative 
setting as monotherapy and in combination with cyto-
toxic chemotherapy for urothelial carcinomas of the 
bladder (eg, NCT02365766 and NCT03661320). Although 
the adjuvant trials have included preplanned cohorts of 
patients with UTUC, no phase 3 trials are underway to 
address the role of immu notherapy in the adjuvant 
treatment of UTUC alone. Both FGFR inhibitors and 
Articles
www.thelancet.com   Published online March 5, 2020   https://doi.org/10.1016/S0140-6736(20)30415-3 9
immune checkpoint inhibitors might, therefore, be 
suitable additions to chemotherapy in future phase 3 
trials that specifically address optimisation of peri opera-
tive treatment in UTUC.
We conclude that adjuvant platinum-based chemo-
therapy should be adopted as a new standard of care for 
patients with locally advanced UTUC for whom systemic 
chemotherapy is not contraindicated. This regimen should 
be routinely considered for all patients in this population, 
and future studies should focus on combi nations with 
novel agents in the adjuvant setting, which might further 
improve the prognosis for locally advanced UTUC.
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